Navigation Links
Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008
Date:2/25/2009

- Exceeds 2008 Projections for Net Operating Income and Year-End Cash

- Achieves 2008 Positive Pro Forma Net Operating Income and Net Income

- Conference Call Webcast Wednesday, February 25, 8:30 a.m. EST at www.isispharm.com

CARLSBAD, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2008 financial results and business highlights. Isis exceeded its 2008 financial guidance by ending 2008 with positive pro forma net income of $3.1 million and positive pro forma net operating income of $226,000. The considerable improvement in Isis' financial results from 2007 was due to a significant increase in revenue that Isis generated in 2008 from its corporate partnerships. On a GAAP basis, Isis' loss from operations of $13.1 million and net loss of $12.0 million also improved significantly from its 2007 loss from operations and net loss. In addition to creating a continuing revenue base, Isis' corporate partnerships have considerably improved its cash position allowing Isis to finish 2008 with $491 million of cash, which does not include the $175 million that Isis received in January 2009 when it completed the sale of its Ibis Biosciences subsidiary to Abbott Molecular Inc (AMI).

"We believe that we are now at the beginning phase of sustained financial strength as evidenced by our 2008 financial results. With the sale of Ibis at the beginning of 2009, we started the year with more than $650 million in cash. In addition, we ended the year with positive pro forma net operating income and net income, further demonstrating our move toward continued financial strength. We expect to continue to benefit financially from the successful execution of our business strategy in 2009 and to move closer
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Lehigh Valley-Based PPO, Valley Preferred, Reports Marked Improvement in Disease Management & Wellness Outcomes
2. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
3. Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results
4. ev3 Inc. Reports 2008 Fourth Quarter and Full-Year Financial Results and 2009 Guidance
5. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
6. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2008
7. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
8. Solta Medical Reports Fourth Quarter and Full Year 2008 Results
9. 1 in 10 Ex-NFL Players Used Steroids, Poll Reports
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
11. Nyer Medical Group, Inc. Reports Revenues of $19.0 Million for the Quarter Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2CMSA Announces New Model ACT Supporting Case Management Programs 55526 1CMSA Announces New Model ACT Supporting Case Management Programs 55526 2CMSA Announces New Model ACT Supporting Case Management Programs 55526 3President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 1President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 2Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 1Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 2Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 3Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 4Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 5Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 6Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 7Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 8Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 9Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 10Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 11